What the company is doing (bench testing and animal implants/explants) is standard procedure with the FDA, this is what all medtech companies have to do. They are generally ongoing anyway . There's been no oversight. All of this has been addressed by the CEO at the AGM and more recently in an Ann: in regards to the pivotal study.
Clinical trials, page-14
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
-0.650(4.44%) |
Mkt cap ! $295.9M | |||
| Open | High | Low | Value | Volume |
| $14.00 | $14.40 | $13.11 | $401.7K | 28.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2157 | $13.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.25 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |